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The nasal airway may be the initial target of a spec-
trum of systemic diseases. Recognition of these signs 
may permit earlier and more effective management of 
the underlying condition. Systemic diseases affecting 
the nasal airway can produce pathologic changes in 
three general ways. First, the general pathophysiol-
ogy of the disease may affect the tissues of the nose 
as in recurrent or severe epistaxis secondary to a 
coagulopathy. Second, the unique mucosal histology 
of the nose may make an otherwise minor pathologic 
process more severe and apparent as seen in heredi-
tary hemorrhagic telangiectasia. In this particular 
disease, telangectasia in the skin cause few symptoms 
whereas in the superficial, easily traumatized vessels 
of the nasal mucosa, severe epistaxis may occur.Third, 
a systemic disease may affect the tissues of the nose 
as part of a symptom complex as seen in Wegener’s 
granulomatosis.
Granulomatous disease
Several granulomatous diseases have a predilection 
to involve tissue in the airways. These include We-
gener’s granulomatosis, Churg-Strauss syndrome, 
and sarcoidosis. These diseases are often character-
ized by local inflammatory response in the airways, 
particularly in the upper nasal passages. Wegener’s 
granulomatosis is perhaps the most common granu-
lomatous disease to affect the upper airway and the 
nasal airway in particular. Sarcoidosis and Churg-
Strauss vasculitis, although much less frequently 
found to involve the nasal airway, also have charac-
teristic findings. 
Wegener’s Granulomatosis
Friedrich Wegener first clearly defined WG as a systemic 
disease in 1939 characterized by necrotizing granulo-
mas with vasculitis of the upper and lower respiratory 
tract, systemic vasculitis, and focal necrotizing or 
proliferative glomerulonephritis [1]. The classic triad 
of WG includes the following organ systems: the upper 
respiratory tract, lungs, and kidneys. Formerly, WG 
was often confused with several other entities causing 
midline granulomas or midface destruction including 
lymphomas, carcinomas and infectious processes. 
WG can now be easily separated with more precise 
nasal biopsies, histopathalogic examination and the 
cytoplasmic antineutrophilic cytoplasmic antibody 
(c-ANCA) test.
The prevalence of WG is estimated to be 3 cases 
per 100,000 while the mean age at diagnosis is 55 
years [2]. Males and females are similarly affected and 
more than 90% of all WG patients are white per recent 
studies. The remaining 1-4% of cases are comprised of 
African-Americans, Hispanics, and Asians [3].
Rhinologic symptoms of patients with WG may include 
nasal congestion, rhinorrhea and, anosmia. These symp-
toms may progress to rhinitis, sinusitis, septal perforation 
and/or nasal airway stenosis. Nasal endoscopy typically 
reveals mucosal cobblestoning, edema, and crusting [4].
Clinical features of WG can be divided into three 
categories. Type 1 patients present with a limited form 
of the disease characterized by upper airway symptoms 
and few systemic findings. They typically present with 
several weeks of symptoms reminiscent to an upper 
respiratory tract infection which are unresponsive to 
antibiotics. There is often associated nasal pain and 
serosanguinous rhinorrhea and crusting. 
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Type 2 patients have systemic features, but their 
initial presentation is similar to type 1. There is a char-
acteristic prolonged upper respiratory tract infection 
with a continued nasal discharge which progresses 
to nasal pain, tenderness, serosanguinous discharge, 
ulceration, and crusting. Pulmonary involvement is 
often present and associated with a cough, hemoptysis 
and cavitary lesions on chest x-ray. 
Type 3 is a widely disseminated form of the systemic 
disease with upper and lower airway involvement, 
cutaneous lesions, and progressive renal involvement. 
Systemic features are more profound and again nasal 
ulcerations and symptoms are present.
Diagnosis
The clinical diagnosis of WG is suggested by the his-
tory and characteristic nasal findings. Laboratory 
values which are often abnormal in WG include the 
erythrocyte sedimentation rate (ESR), hemoglobin, 
serum creatinine and c-ANCA. These serologic find-
ings in conjunction with nasal biopsy can provide a 
definitive diagnosis of WG.
Immunofluorescence is a study which distinguishes 
anti-PR3 antibodies from antimyeloperoxidase antibod-
ies by the pattern of staining: cytoplasmic ANCA for 
anti-PR3, versus perinuclear ANCA for antimyeloperoxi-
dase [5]. The characteristic pattern of coarse granular 
staining of c-ANCA is caused by antibodies against 
proteinase 3 and neutral serine protease present in 
the azurophilic granules of neutrophils. The c-ANCA is 
highly sensitive for WG but a negative c-ANCA does not 
exclude the diagnosis of WG. The specificity of c-ANCA 
for WG has been confirmed in large studies and may 
in some cases preclude the need for biopsy [6,7,8]. The 
c-ANCA titer may be used to monitor disease activity as 
rise in the titer may be predictive of a relapse of disease 
although this concept remains controversial. However, 
it is clinically appropriate to interpret an increase in 
c-ANCA titer as an indicator to closely monitor the 
patient for signs of relapse.
Nasal biopsy may provide supportive evidence for 
the diagnosis. It is important to remove all visible nasal 
crusts followed by liberal removal of tissue from the 
septum, nasal floor, and turbinates in order to provide 
ample tissue for stains and culture [8]. Culture is 
necessary to rule out granulomatous infectious agents 
such as fungi and mycobacteria. 
Because of the non specific nature of many of the 
symptoms of WG, diagnosis and treatment may be 
delayed.
Pathology
The histopathologic features of WG include vasculitis 
of medium and small vessels with intramural eccentric 
necrotizing granulomatous lesions. Typically arteries, 
arterioles, capillaries, venules, and veins are involved. 
Large vessels are rarely affected. There may also be 
microabscesses that enlarge and coalesce into larger 
necrotic areas. 
Treatment
Treatment algorithms are often based on disease se-
verity and the organ system affected [9]. Patients are 
typically treated with immunosuppression in order to 
first induce remission and then adjusted to maintain 
the state of remission. The main agents used to induce 
remission are cyclophosphamide, methotrexate and/or 
glucocorticoids. 
Cyclophosphamide is an alkylating agent which 
impairs DNA replication and transcription. The cur-
rent standard regimen for treatment of WG with cy-
clophosphamide is oral administration of 2mg/kg per 
day with a maximum dose of 200mg/day. It is typically 
continued for 6 months to 1 year and then tapered 
gradually after the disappearance of symptoms.
Methotrexate is an alternative to cyclophosphamide 
in patients with limited forms of WG such as found in 
Type 1 patients. It acts as an antimetabolite and in-
hibits dihydrofolate reductase in order to impair folate 
metabolism. The standard dose begins at 0.25mg/
kg/week which can be increased to 25mg/week. It is 
typically continued for 1 year and may be continued 
indefinitely or tapered or stopped abruptly. 
Glucocorticoids are given concurrently whether 
cyclophosphamide or methotrexate is used. The recom-
mended starting dose is prednisone 0.5-1.0 mg/kg/day 
up to a maximum of 80mg/day [9]. Tapering may begin 
after 1 month with the goal to discontinue completely 
within 6-9 months.
After the symptoms are stabilized WG may be 
effectively maintained on a regime of trimethoprim-
suflamexoxizole [10]. Although the mechanism of ac-
tion of this drug is not known with certainty, it had 
been shown to prevent relapses, and has minimal 
side effects.
New therapeutic agents have been shown to be 
promising in resistant cases. Rituximab a chimeric 
monoclonal antibody has been reported to be effective 
in treating resistant WG [11].
Surgical reconstruction may be used to restore 
function once the disease is in remission. This in-
cludes correction of saddle nose deformity and septal 
perforation repair. Functional endoscopic sinus sur-
gery may benefit select patients with chronic nasal 
crusting. Saline irrigations with or without antibiotics 
are essential to management although nasal debride-
ment may be helpful with mucosal sparing techniques 
and frequent post-operative care to minimize scar 
formation. 
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Sarcoidosis
Sarcoidosis is a chronic systemic granulomatous disease 
capable of involving almost any organ in the body. It 
frequently involves the lymphatic system, lungs, liver, 
spleen, and bones. Although involvement of the epi-
thelium of the upper respiratory tract is comparatively 
infrequent, nasal symptoms may be the first manifesta-
tion of this disease. 
The etiology of sarcoidosis is unknown, but etiologic 
claims have been made for various infective agents, 
chemicals (including beryllium and zirconium), pine pol-
len, and peanut dust [12]. It has also been associated with 
cell-mediated and humoral immune abnormalities.
The clinical course in most cases is benign with 
spontaneous resolution within 2 years although 10% 
may progress to pulmonary fibrosis. The lung is the 
primary organ affected by sarcoidosis. Ninety percent 
of patients will have evidence of thoracic involvement, 
either enlarged intrathoracic lymphnodes or pulmonary 
parenchymal infiltrates. Approximately 40% of patients 
with sarcoidosis will have granulomatous changes in 
extrapulmonary organs. 
The involvement of the nose and paranasal sinuses 
by sarcoidosis is relatively infrequent and most reports 
are anecdotal, so the true incidence of nasal involvement 
is not known with certainty. The observed incidence 
of histologically confirmed nasal involvement in large 
populations of patients with sarcoidosis has ranged 
between 1% and 6% [13, 14]. The most frequent symp-
tom of nasal involvement is nasal obstruction, but, 
epistaxis, dyspnea, nasal pain, epiphora, and anosmia 
may also occur. 
Nasal sarcoidosis commonly affects the mucosa of 
the septum and inferior turbinate. The nasal mucosa 
is usually dry and friable with crusting [15]. Submu-
cosal nodules with a characteristic yellow color may be 
noted. These nodules are the macroscopic presentation 
of intramucosal granulomas which can be identified in 
mucosal biopsies. In more advanced disease, irregular 
polypoid mucosa is seen, which is friable and bleeds 
readily. 
Paranasal sinus involvement in sarcoidosis often 
accompanies nasal mucosal involvement. Mucous mem-
brane thickening or opacification of paranasal sinuses 
occurs. Some patients with nasal sarcoidosis will have 
bony lesions of the nasal bones. The lesions may appear 
as scattered regions of osteoporosis or zones of frank 
destruction. These lesions are a response to granulomas 
within the bone. The suture lines may disappear, but 
no periosteal reaction is seen [16].
Diagnosis
The diagnosis of sarcoidosis is based on a combina-
tion of histologic, radiographic, immunologic, and 
biochemical data. The diagnosis of sarcoidosis of the 
nose and paranasal sinuses is based on the clini-
cal findings of crusting friable nasal mucosa with 
either polypoid changes or characteristic yellowish 
submucosal nodularity. Sinus CT and x-ray will be 
abnormal in most cases of nasal sarcoidosis. Pul-
monary findings of either hilar lymphadenopathy or 
pulmonary fibrosis are commonly found. Laboratory 
findings that may support a presumptive diagnosis 
of sarcoidosis are elevated serum or urinary calcium. 
Radiogallium uptake may be increased in the nasal 
mucosa in sarcoidosis [17]. The diagnosis is confirmed 
by the presence of noncaseating granulomas in the 
nasal mucosa. 
Angiotensin-converting enzyme (ACE) elevations 
occur in 83% of patients with active sarcoidosis. At 
the present time, this test has become very useful for 
the diagnosis of sarcoidosis as well as monitoring for 
relapse. It must be remembered that ACE levels can 
also be elevated in tuberculosis, lymphoma, leprosy, 
and Gaucher’s disease. 
Pathology
Multiple noncaseating granulomas are the charac-
teristic histology feature of sarcoidosis. The sarcoid 
granuloma consists of a central area of tightly packed 
epitheliod cells surrounded by lymphocytes and fibro-
blasts. Multinucleated giant cells up to 150 μm in di-
ameter are frequently found within granulomas. There 
is no specific histologic feature of sarcoidosis, and 
similar granulomas occur in tuberculosis, berylliosis, 
leprosy, hypersensitivity pneumonitis, fungal disease, 
and chronic inflammatory processes [18, 19]. 
Treatment
Most cases of stage I sarcoidosis will undergo spon-
taneous remission within 2 years without specific 
treatment. Sarcoidosis beyond stage I with elevated 
ACE levels or extrapulmonary involvement will usually 
require treatment. This includes most cases of nasal 
sarcoidosis. 
The mainstay of treatment is systemic cortico-
steroids. The majority of patients’ symptoms can be 
controlled with oral prednisone in doses of 10-40 mg 
daily [20]. If nasal symptoms relapse while a patient is 
taking relatively high systemic doses of corticosteroid, 
local treatment with intranasal steroids may be used 
to allow reduction in the oral dosage. 
Methotrexate has been used to treat nasal sar-
coidosis successfully at a dose of 30mg weekly [21]. 
The use of methotrexate should only be considered 
if there are contraindications to the use of systemic 
corticosteroids, since its effectiveness in sarcoidosis 
has not been extensively tested. 
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Churg-Strauss Syndrome
Churg-Strauss syndrome (CSS) is also known as aller-
gic granulomatous angiitis and affects small to medium 
sized vessels. It is a granulomatous vasculitis which is 
characterized by three phases: Phase 1. a prodromal 
phase with allergic rhinitis and asthma; Phase 2. an 
eosinophilic infiltrative phase with chronic eosinophilic 
pneumonia or gastroenteritis; and Phase 3. a systemic, 
life-threatening vasculitis with granulomatous inflam-
mation. CSS is associated with nasal crusting and 
polyposis and may be distinguished from WG by the 
presence of both nasal polyps and asthma in CSS. 
C-ANCA will also be negative in CSS while p-ANCA is 
positive in 70% of patients.. CSS may be distinguished 
from sarcoidosis by the presence of asthma, eosino-
philia, and vasculitis with necrotizing granulomas all 
of which are absent in sarcoidosis [22].
Pathology
Histopathologically, CSS is characterized by necro-
tizing vasculitis of small and medium sized vessels. 
Necrotizing extravascular granulomas may also be 
present. There is prominent eosinophilia of the vessels 
and perivascular tissue. 
Treatment
Glucocorticoids continue to be standard treatment 
for CSS. Cyclophosphamide may be helpful in life 
threatening cases or in patients with poor prognostic 
factors [23].
Neoplastic dieseases
The most notable neoplastic, systemic disease with na-
sal manifestations is nasal T-cell lymphoma. Leukemia 
and B-cell lymphomas may also have nasal presenta-
tions. B-cell lymphomas may cause unilateral nasal 
obstruction by an enlarged nasal or nasopharyngeal 
mass. Acute leukemia may produce symptoms of an 
upper respiratory infection or cause epistaxis second-
ary to friable mucosa in the anterior nose.
T-Cell Lymphoma
Previously known as midline malignant reticulosis or 
polymorphic reticulosis, nasal T-cell lymphoma is a rare 
disease that can be difficult to diagnose. Long term 
remission is only 50% in patients with this disease and 
50% will die from distant extranodal spread or from 
relapses outside of the treatment field [24, 25]. Nasal 
T-cell lymphomas differ phenotypically from lymphomas 
of the paranasal sinuses and in Waldeyer’s ring which 
tend to be of B-cell origin.
Diagnosis
Clinical manifestations of nasal T-cell lymphoma usu-
ally start with nasal obstruction followed by purulent 
rhinorrhea and serosanguinous discharge. As symp-
toms progress, usually unilateral mucosal ulceration 
with extension into the palate, maxillary sinus and 
upper lip help distinguish lymphoma from WG which 
is associated with diffuse nasal mucosal ulceration. 
Mucosa is often pale, friable and extensive crusting is 
often present. Oronasal fistulas often occur as well as 
nasal septal perforations which have been reported in 
40% of cases of nasal T-cell lymphoma [26]. Typically, 
there is an explosive unilateral involvement of one 
side of the nose, face, palate, and/or orbit. Systemic 
symptoms are more notable in advanced cases and 
include malaise, night sweats, febrile episodes and 
arthralgias [27].
Laboratory workup is similar to that for Wegener’s 
granulomatosis. However, it is important to include HIV 
testing. A nasal biopsy may benefit diagnosis if there 
is adequate sampling of both abnormal and adjacent 
normal tissue.
Pathology
T-cell lymphomas have a polymorphic lymphoid in-
filtrate made up of mature, immature and atypical 
lymphocytes, plasma cells, histiocytes, eosinophils, 
and macrophages. The infiltrate is characterized by 
angiocentricity and angioinvasion and can lead to 
vessel occlusion and local tissue infarction. This is 
may lead to the rapid tissue necrosis and ischemia 
seen with nasal T-cell lymphoma. Immunohisto-
chemical studies of biopsy specimens typically dem-
onstrate the presence of T-cell associated markers 
CD2, CD7, CD45RO, CD43 and natural-killer marker 
CD57 [28].
The association of Epstein-Barr virus (EBV) and 
nasal T-cell lymphoma has frequently been reported. 
Various studies report the detection of EBV DNA and 
RNA in tumor cells associated with high titers of EBV 
antibodies in patients with T-cell lymphoma [25, 29, 
30]. The causative role of EBV in the pathogenesis 
of T-cell lymphoma has been strongly suggested but 
remains to be definitively determined. Treatment
Localized disease responds well to radiation 
therapy. Chemotherapy may benefit patients with 
disseminated disease or relapses. A 2004 study 
suggested that high dose chemotherapy as well as 
autologous peripheral blood stem cell transplant 
may be an effective treatment option for relapsed 
nasal T-cell lymphoma [24]. Currently, multiple agent 
chemotherapy in addition to radiation therapy is the 
initial treatment recommendation for nasal T-cell 
lymphoma [25].
O t o l a r y ngo l og i a  Po l s k a  t o m 6 3 ,  n r  3 ,  m a j – c ze r w i e c  2 0 0 9 
ARTYKUŁ REDAKCYJNY / EDITORIAL232
Immunodeficiency diseases
Immunodeficiency is of special importance in the nasal 
manifestations of acquired immune deficiency syn-
drome and the infectious consequences of iatrogenic 
immunodeficiencies resulting from chemotherapy for 
neoplastic and hematologic diseases. These two forms 
of immunodeficiency create difficult problems of diag-
nosis and treatment of infectious diseases of the nose, 
which will become an increasing component of the 
practice of rhinology. 
Sinusitis in the immunocompromised 
patient
Rhinitis and sinusitis in immunocompromised pa-
tients is usually due to the same pathogens affecting 
the general population. There may be more subtle 
signs of bacterial infection but treatment is similar 
including antibiotics and/or surgery. Complications 
including periorbital or orbital abscess may be more 
subtle and open surgical treatment may be insti-
tuted prior to full demonstration of an abscess on 
CT scan.
Fungal sinusitis appears rarely in immunocom-
promised patients but is extremely important to the 
otolaryngologist in terms of diagnosis and treatment. 
Aspergillus sp. and Mucor sp. are the most commonly 
involved fungi. Patients present with bloody nasal 
discharge, facial pain and swelling, fever, and edema. 
The disease often progresses rapidly in an invasive 
manner to cause facial cellulitis, gangrenous mu-
cosal changes in the nose and paranasal sinuses, 
obtundation, cranial nerve palsies, vision loss, and 
proptosis [31].
Diagnosis is established via physical exam findings 
of pale or gray mucosa of the nasal cavity or palate 
or the classic black middle turbinate [32]. Decreased 
pain and sensitivity of the nasal cavity is a suspicious 
sign. Small tissue biopsies should be taken of the 
nasal lesions and sent for culture and microscopic 
examination including GMS stain. CT scan of the 
sinuses may demonstrate a destructive bony lesion 
but can often understate the clinical problem in a 
severely immunocompromised patient. 
Treatment includes standard treatment for febrile 
neutropenia if present, blood glucose control in diabet-
ics as well as medical therapy for biopsy or culture 
confirmed Mucor or Aspergillus. Current antifungal 
therapies include amphotericin B systemically and 
nasal irrigations, voraconazole and posaconazole. 
Aggressive surgical debridement is strongly advocated 
if the patient can tolerate surgical intervention. Surgi-
cal interventions range from endoscopic debridement 
to total maxillectomy with orbital exenteration and 
craniofacial resection. 
Acquired Immunodeficiency 
and the nasal airway
The acquired immunodeficiency syndrome (AIDS) is a 
syndrome characterized by the presence of one or more 
opportunistic diseases that indicate an underlying 
cellular immunodeficiency, without any other known 
cause of immunodeficiency [33]. It is well known that 
the condition is caused by the human immunodefi-
ciency virus which attacks T-helper cells. 
The most common nasal manifestation of AIDS is 
chronic rhinitis. Patients present with drying, crust-
ing, nasal congestion, partial obstruction and pain 
or discomfort. Purulent rhinitis may be seen second-
ary to cytomegalovirus. Other causative agents of 
rhinosinusitis reported in the literature include Strep. 
Pneumoniae, Haemophilus influenzae, Legionella pneu-
mophilia, Alterneria, Cryptococcus neoformans, and 
Acanthomoeba castellani. Treatment of rhinosinusitis 
in HIV/AIDS patients according to Lucente and Meitels 
includes a trial of antibiotics and decongestants ini-
tially. Failure of this trial should be followed by antral 
lavage and culture with directed treatment. If there is 
inadequate response, surgical intervention should be 
undertaken [34].
Benign and malignant neoplasms are also present 
in the patient with AIDS. Patients may complain of 
nasal obstruction and hearing loss or foul-smelling 
nasal discharge. Reported findings upon examination 
and biopsy of the nasal cavity and nasopharynx include 
benign lymphoid hypertrophy and nasal lymphomas. 
Kaposi sarcoma has also been documented in the na-
sal skin, vestibule, cavity, septum, and nasopharynx 
in patients with AIDS [34]. Symptoms can present as 
nasal obstruction, drainage and epistaxis. Physical 
exam may reveal nodular violaceous lesions. Treat-
ment of these neoplasms ranges from supportive care 
to chemotherapy and radiation if warranted. 
Cutaneous diseases
Nasal findings associated with selected autoimmune or 
collagen-vascular disorders are uncommon. However, 
there are a few major disorders with nasal manifesta-
tions which may cause significant morbidity and are 
worthy of mention. They include pemphigus, phemp-
higoid, scleroderma, and Behcet’s disease.
Pemphigus vulgaris
Pemphigus vulgaris is a common mucocutaneous bul-
lous disorder characterized by nonscarring bullous 
dermatitis of presumed autoimmune origin [35]. The 
oral cavity is the most common site involved in the 
head and neck region and only 10% of all patients will 
have involvement of the nasal mucosa. Desquamative 
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ulcerative lesions can be seen and ulceration of the 
nasal septum with anterior perforation has also been 
reported. The external nose is more likely to be affected. 
Steroids are the mainstay of treatment and may have 
to be combined with other immunosuppressants.
Pemphigoid
Pemphigoid is an uncommon disease characterized by 
blisters and scar formation and has a presumed auto-
immune etiology. It can be divided into two categories: 
bullous and cicatricial. Cicatricial pemphigoid is more 
likely to affect the mucosa while bullous pemphigoid 
is confined to skin. Nasal findings occur in 25-50% 
of affected patients [36]. The usual site of involvement 
is the anterior nasal region which is found to painful, 
ulcerative crusting. Scar formation is usually found 
in the nasal valve area but can also affect the naso-
pharynx. Scarring may be bilateral and lead to partial 
or total nasal obstruction [37]. Treatment is usually 
managed by a dermatologist and includes dapsone 
and/or immunosuppressive agents.
Scleroderma
Scleroderma is a systemic disorder of unknown etiol-
ogy. Its characteristics include symmetrical stiffness 
of the skin and vascular insufficiency. Head and neck 
manifestations are very common and mostly affect the 
skin and oral cavity. Nasal findings involve telangec-
tasias of the mucosa leading to epistaxis. Treatment 
is symptomatic.
Behcet’s Disease
Behcet’s disease is characterized by the following triad: 
oral ulceration, genital ulceration, and ocular inflam-
mation. The typical aphthous ulceration found in the 
oral cavity in this disease can also be found in the 
nasal mucosa. These lesions typically heal without 
scarring but can cause rhinorrhea and pain. Treatment 
includes symptomatic care as well as immunosup-
pressive agents.
Mucociliary diseases
A major defense mechanism of the nose and paranasal 
sinuses against infection is the mucociliary system. 
The physiology of this system has only recently come 
under close scrutiny. Its role in the prevention of si-
nusitis is apparent by noting the effects of mucociliary 
deficiencies in dysfunctional cilia syndrome and cystic 
fibrosis. New techniques for evaluating cilia function 
have permitted better diagnosis of these conditions, 
whose detrimental consequences can be controlled 
by early treatment.
Normal mucociliary function in the nose is toward 
the nasopharynx in all parts except for the very an-
terior end of the septum. The direction of mucociliary 
transport is independent of the position of the body 
in reference to gravity. Mucociliary transport can be 
bridged at areas lacking ciliated epithelium by the 
traction exerted by the viscous mucous layer [38]. 
Primary Ciliary Dyskinesia
Primary ciliary dyskinesia was first described in as-
sociation with Kartagener’s syndrome. The dyskinesia 
is characterized by chronic respiratory tract disease 
beginning in childhood leading to a constellation of 
symptoms including chronic rhinitis, sinusitis, bron-
chiectasis, chronic cough, otitis media, and sterility 
[38]. The incidence of primary ciliary dyskinesia is 1 
in 15,000 to 1 in 30,000 and it is suspected to be an 
autosomal recessive disease [39].
Primary ciliary dyskinesia can be diagnosed by 
the saccharin test which is performed by placing a 
tablet of sodium saccharinate just behind the anterior 
aspect of the inferior turbinate. The transit time is 
recorded for the patient to notice a sweet taste after 
the tablet is placed. The maximum normal time is 
typically 30 minutes. This test may be influenced by 
many variables and does not itself identify a specific 
etiology of symptoms. Morphologic studies of the cili-
ated epithelium can confirm the diagnosis, but care 
must be taken to exclude secondary changes due to 
bacterial or viral infections. Management of primary 
ciliary dyskinesia includes antibiotics and nasal irri-
gations. Surgery is indicated for chronic or recurrent 
infections in order to establish a dependent drainage 
pattern. But even with appropriate surgical drainage 
chronic use of antibioticand nasal irrigations will be 
necessary to control symptoms.
Cystic Fibrosis
Cystic fibrosis is the most common fatal inherited 
disease among Caucasians and is autosomal reces-
sive. It affects 1 in 2000 live births and is associated 
with a mutation on chromosome 7q31-32 [40]. Cystic 
fibrosis is a disease affecting the mucous component 
of mucociliary transport rather than the cilia them-
selves as is the case in ciliary dyskinesia. The disease 
is characterized as an exocrinopathy with clinical 
features of chronic lung disease, chronic sinusitis, 
and pancreatic insufficiency [40].
Diagnosis is confirmed by sweat chloride test. 
Specific nasal symptoms include intermittent nasal 
obstruction with clear but thick rhinorrhea and nasal 
polyps. Patients with cystic fibrosis will often have 
grayish-green puttylike material in their sinuses and 
the most common bacteria affecting these sinuses are 
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Pseudomonas aeruginosa and Staphylococcus aureus 
Radiology demonstrates underdevelopment of the si-
nuses, especially of the frontal sinus. 
Treatment of the nasal symptoms of cystic fibrosis 
is important to maintain a patent nasal airway and 
prevent infection. Long term antibiotics may be needed 
and nasal irrigations are often beneficial. Nasal polyp 
and/or sinus surgery may be indicated in cases of failed 
medical management and depends upon the degree of 
nasal obstruction, the severity of sinusitis symptoms, 
and the motivation of the patient and family. Much 
debate and controversy remains surrounding the exact 
role of surgical intervention in these patients.
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